Get the Stockscreener App
1.04
3.70%
-0.04
Opus Genetics Inc stock is traded at $1.04, with a volume of 207.90K.
It is down -3.70% in the last 24 hours and down -8.77% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$1.08
Open:
$1.08
24h Volume:
207.90K
Relative Volume:
0.95
Market Cap:
$32.83M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-0.9541
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
-5.45%
1M Performance:
-8.77%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.02
$1.10
1-Week Range:
$1.02
$1.1432
52-Week Range:
$0.81
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
37000 GRAND RIVER AVE., FARMINGTON HILLS
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.04 | 32.83M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program - GlobeNewswire
Opus Genetics advances gene therapy in pediatric trial - Investing.com India
Opus Genetics advances gene therapy in pediatric trial By Investing.com - Investing.com South Africa
FTI Consulting Expands Transactions Practice with Appointment of Two M&A Experts - The Manila Times
Which NC organizations would be impacted by Trump’s NIH funding cuts? Here’s a list - Charlotte Observer
Opus Genetics revises executive compensation agreements - MSN
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc. - The Manila Times
Portland Investment Counsel Inc. Recognized at the FundGrade A+® Awards - The Manila Times
Mina Sooch Nominates Slate of Director Candidates to the Board of Opus Genetics -February 07, 2025 at 09:15 am EST - Marketscreener.com
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
Opus Genetics sets April 30 for 2025 Annual Meeting - MSN
Avinger Inc adjourns Special Meeting due to lack of quorum - MSN
Opus Genetics revises executive compensation agreements By Investing.com - Investing.com Canada
Opus Genetics Enhances Executive Severance Packages - TipRanks
Applied DNA Sciences fails to secure shareholder vote - MSN
Harmony Biosciences Reports Strong Revenue Growth and Outlines Ambitious 2025 Strategy - MSN
Toyota Tsusho (OTCMKTS:TYHOF) Shares Down 18.7% – Should You Sell? - Defense World
Opus Genetics launches $40M at-the-market equity program - Investing.com
NeoGenomics CEO Chris Smith to retire - MSN
Opus Genetics CEO Magrath George buys $97,600 in stock - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Opus Genetics aligns with FDA on Phase 3 trial for diabetic retinopathy drug - Investing.com Canada
IRD stock touches 52-week low at $0.84 amid market challenges - Investing.com India
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy - The Manila Times
Opus Genetics Secures FDA Agreement for Pivotal Diabetic Retinopathy Treatment Trial - StockTitan
Ocuphire Pharma Sets End-of-Phase 2 Meeting With FDA in Q4 to Discuss Diabetic Retinopathy Treatment - Marketscreener.com
Opus Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a - GlobeNewswire
Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 - Marketscreener.com
AXT Inc (AXTI) Could Be Worth Considering For The Next Few Weeks - Stocks Register
At $0.76 Price, Cumulus Media Inc (CMLS) Is Sitting And Waiting - Stocks Register
Analysts Update Their Estimates For Alpha Teknova Inc - Stocks Register
Analysts Provide An Important Insights On Hallador Energy Co (HNRG) - Stocks Register
Hippo Holdings Inc (HIPO): Major Improvements, Worth A Look - Stocks Register
Telomir Pharmaceuticals Inc (TELO) Recovers 37.62% From Low: Are We There Yet? - Stocks Register
Journey Medical Corp (DERM) Should Be Considered For The Next Few Weeks - Stocks Register
The9 Limited ADR (NCTY)’S 0.19% Increase Makes It Worth Considering Again - Stocks Register
Platinum Group Metals Ltd (PLG): Be Patient, You Will Learn - Stocks Register
Nexgel Inc (NXGL) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Cel-Sci Corp (CVM) Stock Behavior Is Not Predictable - Stocks Register
Opus Genetics president Benjamin Yerxa acquires $9,834 in stock - Investing.com India
Opus Genetics president Benjamin Yerxa acquires $9,834 in stock By Investing.com - Investing.com Canada
Opus Genetics Inc CEO George Magrath Purchases 100,000 Shares - GuruFocus.com
FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World
Opus Genetics Inc (IRD) Quarterly 10-Q Report - Quartzy
Opus Genetics reinstated with a Buy at H.C. Wainwright - Yahoo Finance
IRD stock touches 52-week low at $1.07 amid market challenges - Investing.com India
Opus Genetics (IRD) Stock Chart and Price History 2024 - MarketBeat
Wainwright sets stock target on Opus Genetics, cites 2025 catalysts By Investing.com - Investing.com UK
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):